Altimmune, Inc. (ALT)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $253.3M
- P/E ratio
- —
- EPS
- —
- Volume
- 2,605,019
- 52-week high
- —
- 52-week low
- —
- Open
- $2.89
- Day high
- $2.91
- Day low
- $2.79
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $41K | -$88.09M | -$1.00 |
| 2024 | $20K | -$95.06M | -$1.34 |
| 2023 | $426K | -$88.45M | -$1.66 |
| 2022 | -$68K | -$84.71M | -$1.81 |
| 2021 | $4.41M | -$97.09M | -$2.35 |
About Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
- CEO
- Jerome Benedict Durso
- Employees
- 57
- Country
- US
- IPO date
- May 26, 2017
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Altimmune, Inc.'s stock price today?
- ALT is trading at $2.81 as of Jul 20, 2026.
- What is Altimmune, Inc.'s market cap?
- Altimmune, Inc. (ALT) has a market capitalization of $253.3M.
- Does Altimmune, Inc. pay a dividend?
- Altimmune, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Altimmune, Inc. in?
- Altimmune, Inc. operates in the Healthcare sector.